Madrigal Pharmaceuticals Inc
MDGL
ISIN null / Valor 33395434
Madrigal Pharmaceuticals Inc
UMushroom community rating:
About company
Madrigal Pharmaceuticals Inc. is a biopharmaceutical entity focused on the development of innovative treatments for nonalcoholic steatohepatitis (NASH), a condition also referred to as metabolic dysfunction associated steatohepatitis (MASH). The company has made significant strides in this therapeutic area, with its first therapy receiving accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of adults exhibiting moderate to advanced liver fibrosis, which corresponds to stages F2 to F3 fibrosis, a critical subset of the NASH patient population. Furthermore, Madrigal is advancing its research and development efforts by conducting a Phase 3 trial aimed at evaluating the efficacy of its therapy in treating NASH with compensated cirrhosis, demonstrating its commitment to addressing the unmet medical needs within this patient community.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (17.11.2025):
Madrigal Pharmaceuticals Inc reported its financial results for the third quarter of 2025, highlighting significant growth in net revenues driven by Rezdiffra™, alongside higher operating expenses reflecting strategic investments. The company posted net sales of $287.3 million compared to $62.2 million in the prior year period, maintained strong liquidity with $1.1 billion in cash and marketable securities, and advanced its pipeline with new licensing agreements and patent protection extending Rezdiffra’s market exclusivity.
Net Sales Growth
Rezdiffra™ net sales reached $287.3 million in Q3 2025, up sharply from $62.2 million in the comparable prior period, with over 29,500 patients using the drug as of September 30, 2025.
Operational Expenses & Investment
Operating expenses increased to $401.2 million, driven by higher R&D expenditures of $174.0 million and SG&A expenses of $209.1 million, reflecting increased investments in clinical trials, commercialization efforts, and strategic licensing activities.
Liquidity Position
Madrigal’s liquidity remained robust with cash, cash equivalents, restricted cash, and marketable securities totaling $1.1 billion as of September 30, 2025, bolstered by a senior secured credit facility that helped refinance previous obligations.
Strategic Pipeline Advances
The company advanced its pipeline by completing a global licensing agreement with CSPC Pharma for an oral GLP-1 to be developed in combination with Rezdiffra™, secured a new Orange Book patent for protection through 2045, and launched Rezdiffra in Germany following European Commission approval.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
12445 M
Market cap (USD)
567,226
Daily traded volume (Shares)
315 / 307.96
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
